CD44 and colorectal carcinoma: To further investigate the role of Nrf2 in CRC cell resistance to ferroptosis, we treated the RSL3 and Erastin-induced CRC cells with Nrf2 inhibitor, NRF2-IN-1, or Nrf2 activator, TAT-14.